JNJulie Neven

Julie Neven

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Julie Neven has a total of 7 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Recessive congenital methemoglobinemia: a systematic review of reported cases

    by Julie Neven, Tessi Beyltjens, Marije Meuwissen, Barbara De Bisschop, Jason Bouziotis, Machiel van Den Akker

    Background: Recessive congenital methemoglobinemia (RCM) is a rare autosomal recessive disorder characterized by a deficiency of NADH-cytochrome b5 reductase. Under normal conditions, cytochrome b5 reductase and NADH reductase maintain methemoglobin in the physiological range by keeping heme iron in the Fe 2 + state. RCM presents in two clinical forms. Type I presents with isolated cyanosis, while type II presents also with severe neurocognitive manifestations. Genetic analysis of the CYB5R3 gene is often used for diagnosis. Treatment with methylene blue, ascorbic acid, or riboflavin can reduce cyanosis, but does not affect neurological outcomes. Main body: We conducted a systematic review of RCM, identifying all previously reported cases, including one from our center. In addition, we conducted a meta-analysis of individual participant data and provided a comprehensive review of clinical manifestations, genotype-phenotype correlations and treatment options, as well as proposing a diagnostic flow chart. Conclusion: In the case of RCM, diagnosis is primarily achieved through genetic analysis based on direct sequencing. The described pathogenic variants are specific to either type I or type II RCM when considered in combination with their allelic variants in compound heterozygous cases. Well known variants such as c.757G>A is associated with type I in both homo- and heterozygous state. Whereas c.226G> is associated with type I in compound heterozygous state with c.173G>A or c.827C>T and type 2 in homozygous state. Similar results are observed for multiple other variants. Ascorbic acid is the most commonly used treatment. Clinical trial number: Not applicable.


  • Open Access

    Imerslund-Gräsbeck syndrome: a comprehensive review of reported cases

    by Sandra D.K. Kingma, Julie Neven, An Bael, Marije E.C. Meuwissen, Machiel van Den Akker

    Imerslund-Gräsbeck syndrome (IGS) is a rare autosomal recessive disorder characterized by vitamin B12 malabsorption. Most patients present with non-specific symptoms attributed to vitamin B12 deficiency, and proteinuria. Patients may if untreated, develop severe neurocognitive manifestations. If recognized and treated with sufficient doses of vitamin B12, patients recover completely. We provide, for the first time, an overview of all previously reported cases of IGS. In addition, we provide a complete review of IGS and describe two new patients.